HPG1860 Market Size, Forecast, and Emerging Insight - 2032

"HPG1860 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about HPG1860 for Non-alcoholic Steatohepatitis (NASH) in the seven major markets. A detailed picture of the HPG1860 for NASH in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the HPG1860 for NASH. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the HPG1860 market forecast analysis for NASH in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in NASH.

Drug Summary:

HPG1860 is an investigational potent and selective full FXR agonist with a non-bile acid scaffold. Through regulation of gene expression of bile acids, FXR serves as a key controller of bile acid homeostasis. FXR has been studied for its role in modulating inflammation, and the expression of FXR is down-regulated during NASH development. HPG1860 exhibited superb efficacy and safety in preclinical, Phase I and IIa clinical trials.

Hepagene plans to submit an abstract with detailed data from the RISE Study to an upcoming scientific conference. Based on the positive results of the Phase IIa trial, Hepagene continues with the current clinical development plan, including a combination trial of HPG1860 with HPG7233, a thyroid hormone receptor beta agonist (THR-B) developed in-house to treat NASH.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the HPG1860 description, mechanism of action, dosage and administration, research and development activities in Non-alcoholic Steatohepatitis (NASH).
• Elaborated details on HPG1860 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the HPG1860 research and development activities in NASH across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around HPG1860.
• The report contains forecasted sales of HPG1860 for NASH till 2032.
• Comprehensive coverage of the late-stage emerging therapies for NASH.
• The report also features the SWOT analysis with analyst views for HPG1860 in NASH.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

HPG1860 Analytical Perspective by DelveInsight

• In-depth HPG1860 Market Assessment

This report provides a detailed market assessment of HPG1860 for Non-alcoholic Steatohepatitis (NASH) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

• HPG1860 Clinical Assessment

The report provides the clinical trials information of HPG1860 for Non-alcoholic Steatohepatitis (NASH) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Non-alcoholic Steatohepatitis (NASH) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence HPG1860 dominance.
• Other emerging products for NASH are expected to give tough market competition to HPG1860 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of HPG1860 in NASH.
• Our in-depth analysis of the forecasted sales data of HPG1860 from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the HPG1860 in NASH.

Key Questions:

• What is the product type, route of administration and mechanism of action of HPG1860?
• What is the clinical trial status of the study related to HPG1860 in Non-alcoholic Steatohepatitis (NASH) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the HPG1860 development?
• What are the key designations that have been granted to HPG1860 for NASH?
• What is the forecasted market scenario of HPG1860 for NASH?
• What are the forecasted sales of HPG1860 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to HPG1860 for NASH?
• Which are the late-stage emerging therapies under development for the treatment of NASH?